MEDIUM confidence: 100% data completeness, but the composite (52) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $63.5B— | $62.9B-0.9% | $53.7B-14.6% | $53.6B-0.3% | $55.3B+3.2% |
| EPS (dil.) | $5.36— | $2.98-44.4% | $3.26+9.4% | $2.81-13.8% | $2.65-5.7% |
| Free Cash Flow | $5.8B— | $3.7B-37.0% | $3.0B-19.3% | $3.2B+6.6% | $2.8B-11.3% |
| Gross Margin | 21.1% | 19.5%-1.6pp | 21.4%+1.9pp | 22.1%+0.6pp | 20.0%-2.1pp |
| Operating Margin | 8.4% | 7.2%-1.2pp | 6.4%-0.8pp | 7.1%+0.7pp | 6.6%-0.6pp |
| Net Margin | 10.3% | 5.0%-5.3pp | 6.1%+1.1pp | 5.2%-0.9pp | 4.6%-0.6pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net insider -$2.6M over 180 days (0 open-market buys, 6 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $19 avg across 5 analysts.
Buy-rated share 21% → 12% over ~3 months (-9pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| May 2026 | $0.71 | $0.86 | +21.0% |
| Feb 2026 | $0.77 | $0.81 | +5.9% |
| Nov 2025 | $0.92 | $0.93 | +1.0% |
| Aug 2025 | $0.74 | $0.75 | +0.7% |
| May 2025 | $0.78 | $0.71 | -8.4% |
| Feb 2025 | $0.75 | $0.74 | -0.8% |
| Nov 2024 | $0.93 | $0.93 | +0.0% |
| Aug 2024 | $0.86 | $0.83 | -3.5% |
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 2.4%/yr (revenue basis).
Base free cash flow $3.0B (avg FY2023–FY2025; latest year $2.8B) · equity value $27.7B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 52 for HPQ indicates a neutral outlook, with the stock exhibiting strong momentum, scoring 64 in this category, driven by a 45.8% return over the past three months and a bullish moving average trend. However, this is offset by lower scores in value, growth, and profitability, with a P/E of 11.0 and ROE of -473.4% being notable. The short-term score is 8 points higher than the long-term score, suggesting some near-term strength. Overall, HPQ trades at a reasonable valuation but exhibits weak growth and profitability metrics.